2020 American Transplant Congress
Granulocyte Colony Stimulating Factor: Trigger of Rejection in Lung Transplantation?
*Purpose: Granulocyte colony stimulating factor (GCSF) is a management strategy for post-transplant neutropenia, but may increase the risk of rejection in lung transplant recipients (LTRs).…2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…2020 American Transplant Congress
Filgrastim Utilization Evaluation in Solid Organ Transplant Recipients
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Neutropenia occurs in up to 40% of kidney and liver transplant (txp) recipients and has been associated with higher mortality rates in liver txp.…2020 American Transplant Congress
Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens
Pharmacy, Ann and Robert H. Lurie Children's Hospital, Chicago, IL
*Purpose: Valganciclovir (VGCV) is FDA-approved for CMV prophylaxis in children aged one month to sixteen years old using the Pescovitz algorithm (7 x body surface…2020 American Transplant Congress
Outcomes in Liver Transplantation with Use of Granulocyte-Colony Stimulating Factor
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Questions remain if treatment with a granulocyte-colony stimulating factor (G-CSF) impacts clinical outcomes after liver transplant. The purpose of this study was to compare…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…2019 American Transplant Congress
Efficacy of Filgrastim in Solid Organ Transplant Recipients
*Purpose: Neutropenia frequently occurs after solid organ transplantation (SOT) due to immunosuppression, antiviral prophylaxis, or viral infections. Immunosuppression reduction or antiviral prophylaxis minimization can lead…2019 American Transplant Congress
Alemtuzumab Induction in Living Donor Renal Transplantation
The Ohio State University Wexner Medical center, Columbus, OH
*Purpose: About 15% of kidney transplant (KT) recipients receive alemtuzumab (ALM) for induction. The aim of this study was to review outcomes in living donor…2019 American Transplant Congress
Safety Outcomes in Elderly Patients Who Receive Alemtuzumab Induction for Kidney Transplant
Ochsner Clinic Foundation, New Orleans, LA
*Purpose: As a consequence of natural immunosenescence, elderly patients may not require as potent immunosuppression as their younger counterparts. Optimal induction regimens in this population,…2018 American Transplant Congress
A Protocol for the Management of Alemtuzumab Induced Leukopenia in Kidney Transplant Recipients
University of Maryland Medical Center, Baltimore.
Purpose: Leukopenia is a common complication following alemtuzumab induction in kidney transplant recipients (KTR), often limiting its use. Our institution developed a protocol to manage…
American Transplant Congress abstracts